Paris, France, and Nes Ziona, Israel, Wednesday May 14th – The privately-held biotechnology company Sepal Pharma (www.sepalpharma.com), specialized in the development of novel anti-cancer drug-candidates derived from the jasmonate family of compounds, today announced the appointment of Dr. Frédéric Revah as Chief Executive Officer M. Revah has more than 20 year experience in the pharmaceutical and biotechnology industries, as well as in the academic sector. He joined Sepal Pharma in May 2008 and is based in Paris.
“I am very happy to be heading up Sepal Pharma where I will be working with a dynamic and experienced team,” said Dr. Frédéric Revah, CEO of Sepal Pharma. “I am very impressed with the company’s breakthrough technology approach, solid IP and unique internal know-how, as well as the high potential of its drug-candidate portfolio. Sepal’s jasmonate derivatives, have the potential of generating a unique novel therapeutic family for the treatment of cancer.” added Frédéric Revah.
Laure Perret Chargée de Communication Tél. : 01 41 22 07 30 Fax. : 01 41 10 84 47 laure@alizerp.com
Alize RP 69, rue d'Aguesseau 92 100 Boulogne-Billancourt
